UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000021813 |
|---|---|
| Receipt number | R000024452 |
| Scientific Title | A phase III study comparing nivolumab with nivolumab plus docetaxel in patients with previously treated advanced non-small-cell lung cancer: a randomized phase II/III trial(TORG1630) |
| Date of disclosure of the study information | 2016/05/01 |
| Last modified on | 2022/09/02 09:46:23 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2016/04/07 10:21:41 | ||
| 2 | Update | 2016/04/07 10:26:48 | Email |
|
| 3 | Update | 2016/05/09 09:22:00 | Anticipated trial start date |
|
| 4 | Update | 2016/08/17 15:21:50 | Organization Organization |
|
| 5 | Update | 2016/10/11 15:04:27 | Anticipated trial start date |
|
| 6 | Update | 2016/10/11 15:04:27 | Anticipated trial start date |
|
| 7 | Update | 2017/02/03 20:43:05 | Public title Public title Acronym Acronym |
|
| 8 | Update | 2017/02/03 20:54:36 | Developmental phase Primary outcomes Primary outcomes Key secondary outcomes Key secondary outcomes |
|
| 9 | Update | 2017/02/03 20:56:52 | Anticipated trial start date |
|
| 10 | Update | 2017/02/03 20:57:39 | Date of protocol fixation |
|
| 11 | Update | 2017/04/23 09:05:22 | Anticipated trial start date |
|
| 12 | Update | 2017/12/11 09:27:05 | Recruitment status Anticipated trial start date |
|
| 13 | Update | 2018/04/10 15:17:13 | Anticipated trial start date |
|
| 14 | Update | 2019/04/10 09:45:49 | Date of IRB Last follow-up date |
|
| 15 | Update | 2019/11/12 09:50:57 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Organization Organization Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel Secondary IDs Study ID_1 Org. issuing International ID_1 Org. issuing International ID_1 |
|
| 16 | Update | 2020/07/13 16:42:53 | Recruitment status |
|
| 17 | Update | 2020/10/10 11:35:20 | Number of participants that the trial has enrolled |
|
| 18 | Update | 2020/11/26 10:02:07 | Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 19 | Update | 2021/11/08 11:10:25 | Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 20 | Update | 2022/08/30 13:57:39 | Recruitment status |
|
| 21 | Update | 2022/08/30 15:25:36 | URL releasing protocol Publication of results URL related to results and publications Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
| 22 | Update | 2022/08/30 15:28:48 | Primary outcomes Primary outcomes Key secondary outcomes |
|
| 23 | Update | 2022/08/30 15:41:58 | Zip code Address Address TEL Zip code Address Address TEL Name of person sending information Name of person sending information Organization1 Address1 Tel1 Email1 Organization |
|
| 24 | Update | 2022/08/30 16:15:33 | Recruitment status |
|
| 25 | Update | 2022/08/31 10:45:00 | Results Results Outcome measures |
|
| 26 | Update | 2022/09/02 09:46:23 | Results Results |
